Companies: 10,795·Total market cap: $144.5T

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATENASDAQHealthcare● Active

$1.91

$-0.07(-3.54%)

Market Cap$222627690

P/E Ratio—

52W High$2.88

52W Low$0.91

Avg Volume2.7M

Open$2.00

Beta2.52

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Fate Therapeutics, Inc.（FATE）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · FATE · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-1.09Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$6.3MFull revenue history

Dividend Yield不分红Dividend history

Shares Outstanding118.8MShares outstanding history

Next EarningsAug 11, 2026Est.Earnings history

探索 Fate Therapeutics, Inc. 数据

分析师预测$6 · Buy

股息不分红

营收$6.6M-51.24%

盈利EPS $-1.15+29.88%

财务快照

FY 2025Revenue$6.6M▼ 51.24% YoY

202320242025

FY 2025Net Income-$136.3M▲ +26.82% YoY

202320242025

FY 2025EPS$-1.15▲ +29.88% YoY

202320242025

TTM:Revenue: $6.3MNet Income: -$129.9MEPS: $-1.09View income statement →

分析师评级与目标价

Buy31 位分析师

Strong Buy

0

Buy

16

Hold

13

Sell

2

Strong Sell

0

12-Month Price Target

$4.00Low

$1.91Current

$5.50Avg Target上涨空间 187.96%

$7.00High

合计: 31 · 买入占比: 51.6%

根据过去 3 个月内 31 位华尔街分析师，FATE 共识评级为 Buy，12 个月平均目标价 $5.50 （较现价 $1.91 上涨空间 187.96%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Fate Therapeutics, Inc.

$1.91-3.54%$222.6M #2

Acumen Pharmaceuticals, Inc.

$2.17+0.93%$131.4M #3

$1.64+0.31%$182.1M #4

Corbus Pharmaceuticals Holdings, Inc.

$7.56+0.00%$94.8M #5

Inovio Pharmaceuticals, Inc.

$1.09+1.87%$58.4M #6

Molecular Partners AG

$3.95-3.66%$148.2M

股票表现

1D-3.54%

1W-23.90%

1M-20.08%

3M+43.61%

YTD+94.38%

1Y+25.66%

5Y-97.59%

关于 Fate Therapeutics, Inc.

CEOBahram Valamehr

IPO DateOct 1, 2013

Employees181

CountryUS

Websitefatetherapeutics.com

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and va…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Fate Therapeutics, Inc.（FATE）是 Biotechnology 行业的 Healthcare 类公司，于 Oct 1, 2013 在 NASDAQ 上市。截至最近交易日，FATE 股价为 $1.91，市值约为 $222.6M。过去12个月累计回报 +25.66%，年初至今回报 +94.38%。

根据 31 位华尔街分析师，Fate Therapeutics, Inc. 股票共识评级为Buy，12个月平均目标价为 $5.50。2025 财年 Fate Therapeutics, Inc. 营收 $6.6M，净利润 -$136.3M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Fate Therapeutics, Inc.（FATE）股价为 $1.91，在 NASDAQ 上市，52周区间为 $0.91 – $2.88。

FATE 最新股价FATE quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议